IS4479A - Aðferð og lyfjablöndur til að koma af stað frumueitursvörun T-eitilfrumna - Google Patents

Aðferð og lyfjablöndur til að koma af stað frumueitursvörun T-eitilfrumna

Info

Publication number
IS4479A
IS4479A IS4479A IS4479A IS4479A IS 4479 A IS4479 A IS 4479A IS 4479 A IS4479 A IS 4479A IS 4479 A IS4479 A IS 4479A IS 4479 A IS4479 A IS 4479A
Authority
IS
Iceland
Prior art keywords
initiating
preparations
cell lymphoma
lymphoma response
response
Prior art date
Application number
IS4479A
Other languages
English (en)
Inventor
Raychaudhuri Syamal
H. Rastetter William
Original Assignee
Biogen Idec Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc. filed Critical Biogen Idec Inc.
Publication of IS4479A publication Critical patent/IS4479A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
IS4479A 1994-12-07 1997-05-07 Aðferð og lyfjablöndur til að koma af stað frumueitursvörun T-eitilfrumna IS4479A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/351,001 US5709860A (en) 1991-07-25 1994-12-07 Induction of cytotoxic T-lymphocyte responses
PCT/US1995/015433 WO1996017863A1 (en) 1994-12-07 1995-11-29 Induction of cytotoxic t-lymphocyte responses

Publications (1)

Publication Number Publication Date
IS4479A true IS4479A (is) 1997-05-07

Family

ID=23379172

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4479A IS4479A (is) 1994-12-07 1997-05-07 Aðferð og lyfjablöndur til að koma af stað frumueitursvörun T-eitilfrumna

Country Status (33)

Country Link
US (2) US5709860A (is)
EP (1) EP0801656A4 (is)
JP (1) JPH10510264A (is)
CN (2) CN1515319A (is)
AP (1) AP661A (is)
AR (1) AR002255A1 (is)
AU (1) AU699044B2 (is)
BG (1) BG63262B1 (is)
BR (1) BR9509872A (is)
CA (1) CA2204738A1 (is)
CZ (1) CZ293439B6 (is)
EE (1) EE03569B1 (is)
FI (1) FI972431A0 (is)
GE (1) GEP20012556B (is)
HK (1) HK1008226A1 (is)
HU (1) HUP9800946A2 (is)
IS (1) IS4479A (is)
LT (1) LT4308B (is)
LV (1) LV11866B (is)
MD (1) MD1586G2 (is)
MX (1) MX9704097A (is)
NO (1) NO972521L (is)
NZ (1) NZ298582A (is)
OA (1) OA10736A (is)
PL (1) PL183954B1 (is)
RO (1) RO120065B1 (is)
RU (1) RU2201253C2 (is)
SI (1) SI9520148A (is)
SK (1) SK71397A3 (is)
TJ (1) TJ384B (is)
TW (1) TW487575B (is)
UA (1) UA49814C2 (is)
WO (1) WO1996017863A1 (is)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
CA2142007C (en) * 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
ZA988461B (en) * 1997-09-18 1999-03-30 Idec Pharma Corp Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
AU3344299A (en) * 1998-04-20 1999-11-08 Shionogi & Co., Ltd. Th2-migration promoters containing w/o emulsions
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
JP3952129B2 (ja) 1999-02-18 2007-08-01 セイコーエプソン株式会社 半導体装置、実装基板及びその製造方法、回路基板並びに電子機器
EP1163001A2 (en) * 1999-03-24 2001-12-19 The Secretary of State for Defence Vaccine composition
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
FR2805163A1 (fr) * 2000-02-21 2001-08-24 Pf Medicament Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale
AU2001276831A1 (en) * 2000-06-22 2002-01-02 Rxkinetix, Inc. Delivery vehicle composition and methods for delivering antigens and other drugs
FR2814957B1 (fr) * 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
US20070073047A1 (en) * 2002-06-10 2007-03-29 Biogen Idec Ma Inc. Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
AU2003254792A1 (en) * 2002-08-02 2004-02-23 Sumitomo Pharmaceuticals Company, Limited Bacterial cell wall skeleton component preparaion
WO2004027041A2 (en) 2002-09-19 2004-04-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
ATE465753T1 (de) * 2002-10-21 2010-05-15 Eisai Inc Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
EP1572968B1 (en) 2002-10-29 2009-04-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lutzomyia longipalpis polypeptides and methods of use
CA2564180A1 (en) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical preparation containing bacterial cell wall skeleton component
EP1942932B1 (en) 2005-08-08 2013-05-08 Oregon Health and Science University Inactivating pathogens with hydrogen peroxide for vaccine production
US20100130425A1 (en) 2005-09-09 2010-05-27 Oregon Health & Science University Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
BRPI0708865A8 (pt) 2006-03-14 2019-01-22 Univ Oregon Health & Science métodos para produzir uma resposta imune à tuberculose
WO2007124133A2 (en) 2006-04-20 2007-11-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on shiga toxin type 1 protein
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8859218B2 (en) 2008-06-13 2014-10-14 Oncohealth Corp. In situ detection of early stages and late stages HPV infection
AU2008221383B2 (en) 2007-02-28 2012-09-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
US9005631B2 (en) 2008-08-04 2015-04-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Membrane proximal region of HIV gp41 anchored to the lipid layer of a virus-like particle vaccine
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
CN102449479B (zh) 2009-05-07 2015-11-25 安科健康公司 鉴别高度或≥cin2用于人乳头瘤病毒(hpv)与hpv相关癌症的早期及晚期检测、筛检和诊断
CA2776922A1 (en) 2009-10-07 2011-04-14 Uvic Industry Partnerships Inc. Vaccines comprising heat-sensitive transgenes
WO2011047340A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
CN102713629B (zh) 2009-11-20 2016-02-24 俄勒冈健康科学大学 用于检测结核分枝杆菌感染的方法
WO2011084598A1 (en) 2010-01-08 2011-07-14 Oncohealth Corporation High throughput cell-based hpv immunoassays for diagnosis and screening of hpv-associated cancers
WO2011112599A2 (en) 2010-03-12 2011-09-15 The United States Of America, As Represented By The Secretary. Department Of Health & Human Services Immunogenic pote peptides and methods of use
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
CN102125698A (zh) * 2010-11-29 2011-07-20 昆明理工大学 具有正常免疫功能的小鼠移植肿瘤模型的建立方法
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2012284122B2 (en) 2011-07-18 2017-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for inhibiting polyomavirus-associated pathology
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
WO2013152352A1 (en) 2012-04-06 2013-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Live, attenuated rubella vector to express vaccine antigens
EP2850431B1 (en) 2012-05-16 2018-04-18 Immune Design Corp. Vaccines for hsv-2
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
ES2752190T3 (es) 2012-09-14 2020-04-03 Us Health Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
WO2014062778A1 (en) 2012-10-19 2014-04-24 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10286050B2 (en) 2013-12-13 2019-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multi-epitope TARP peptide vaccine and uses thereof
US9931393B2 (en) 2013-12-20 2018-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic JC polyomavirus compositions and methods of use
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CA2994694A1 (en) 2015-08-03 2017-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
KR102486307B1 (ko) * 2016-03-17 2023-01-09 버클리 라잇츠, 인크. 미세유체 디바이스에서의 t 림프구들의 선택 및 클로닝
EP3454894B1 (en) 2016-05-10 2022-07-27 Najit Technologies, Inc. Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
US11235046B2 (en) 2017-11-04 2022-02-01 Nevada Research & Innovation Corporation Immunogenic conjugates and methods of use thereof
CN113454100A (zh) 2018-12-04 2021-09-28 洛克菲勒大学 Hiv疫苗免疫原
TW202214294A (zh) 2020-09-30 2022-04-16 美商碩騰服務公司 具有ｈｙａＣ及ｎａｎＰ缺失之新穎多殺性巴斯德氏菌株及疫苗

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117113A (en) * 1974-06-25 1978-09-26 National Research Development Corporation Immunological preparations
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
US5234683A (en) * 1985-06-18 1993-08-10 Emory University Method of stimulating the immune system
US5114708A (en) * 1985-06-18 1992-05-19 Emory University Method for stimulating growth in animals
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
EP0289550B1 (en) * 1986-10-20 1996-04-10 Chiron Corporation Vaccine for use in the therapeutic treatment of hsv
US4778784A (en) * 1987-01-07 1988-10-18 Baylor College Of Medicine Cyclic peptide and method of use for inducing an immunological response to hepatitis B virus
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
CA1338618C (en) * 1987-11-03 1996-10-01 Noelene E. Byars Vaccine adjuvant
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH0832638B2 (ja) * 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
DE4018442A1 (de) * 1990-06-08 1991-12-12 Boehringer Mannheim Gmbh Rekombinante dna und verfahren zur herstellung chimaerer antikoerper
AU1025692A (en) * 1991-02-06 1992-08-13 Ciba-Geigy Ag Novel chimeric antiidiotypic monoclonal antibodies
US5585103A (en) * 1991-07-25 1996-12-17 Idec Pharmaceutical Corporation Induction of cytotoxic T-lymphocyte responses
DE4443414A1 (de) * 1994-12-07 1996-06-13 Basf Ag Benzopyranfarbstoffe und deren Zwischenprodukte
US7735069B2 (en) 2006-02-09 2010-06-08 International Business Machines Corporation Creating software debug breakpoints activated by specific call patterns
US8919787B1 (en) 2010-10-08 2014-12-30 James Timothy Wilcher Reciprocating tool attachment assembly and methods

Also Published As

Publication number Publication date
CN1515319A (zh) 2004-07-28
AR002255A1 (es) 1998-03-11
MD1586F2 (en) 2001-01-31
EE03569B1 (et) 2001-12-17
PL183954B1 (pl) 2002-08-30
AP661A (en) 1998-08-19
SI9520148A (sl) 1998-06-30
CA2204738A1 (en) 1996-06-13
US5695770A (en) 1997-12-09
AP9701056A0 (en) 1997-10-31
LT97115A (en) 1997-11-25
HUP9800946A2 (hu) 1998-07-28
TW487575B (en) 2002-05-21
FI972431A (fi) 1997-06-06
CZ293439B6 (cs) 2004-04-14
OA10736A (en) 2002-12-11
CN1109046C (zh) 2003-05-21
TJ384B (en) 2004-07-08
EE9700100A (et) 1997-10-15
FI972431A0 (fi) 1997-06-06
MX9704097A (es) 1998-07-31
JPH10510264A (ja) 1998-10-06
EP0801656A4 (en) 2004-06-30
GEP20012556B (en) 2001-10-25
WO1996017863A1 (en) 1996-06-13
US5709860A (en) 1998-01-20
BG63262B1 (bg) 2001-07-31
NO972521D0 (no) 1997-06-03
BR9509872A (pt) 1997-11-25
NO972521L (no) 1997-08-06
CZ174197A3 (en) 1997-10-15
SK71397A3 (en) 1997-11-05
CN1175260A (zh) 1998-03-04
LV11866B (en) 1998-01-20
HK1008226A1 (en) 1999-05-07
PL320612A1 (en) 1997-10-13
MD970199A (en) 1999-02-28
LV11866A (lv) 1997-10-20
BG101656A (en) 1998-02-27
RU2201253C2 (ru) 2003-03-27
EP0801656A1 (en) 1997-10-22
AU699044B2 (en) 1998-11-19
MD1586G2 (ro) 2001-10-31
AU4410496A (en) 1996-06-26
LT4308B (lt) 1998-03-25
UA49814C2 (uk) 2002-10-15
RO120065B1 (ro) 2005-08-30
NZ298582A (en) 1999-10-28

Similar Documents

Publication Publication Date Title
IS4479A (is) Aðferð og lyfjablöndur til að koma af stað frumueitursvörun T-eitilfrumna
DE69428061D1 (de) Paralleles Fehlerdiffusionsverfahren und -gerät
DK0825946T3 (da) Fremgangsmåde til lastning og behandling af hydrocarboner
DE69415180D1 (de) Paralleles Fehlerdiffusionsverfahren und -gerät
DK0996728T3 (da) Forbedrede anti-IgE antistoffer og fremgangsmåde til forbedring af antistoffer
DK0616639T3 (da) Indretning og fremgangsmåde til isolering og oprensning af nukleinsyrer
NO985278D0 (no) Elektromagnetiske-til-akustiske og akustiske-til-elektro-magnetiske forsterkere og fremgangsmÕter for bruk av disse
NO964217D0 (no) Fremgangsmåte og anordning relatert til telekommunikasjonssystemer
IS5388A (is) Aðferð og kerfi til vinnslu hringinga
DE69321660D1 (de) Diffusionsverbindungsverfahren
DK0978115T3 (da) System og fremgangsmåde til styring af et aktivt matrixdisplay
NO972578L (no) FremgangsmÕte og anordning for forsegling
FI961154A (fi) Menetelmä ja järjestely matkapuhelimen käytön rajoittamiseksi
DE69628873D1 (de) Ausrichtgerät und -verfahren
DK0925614T3 (da) Fremgangsmåde til driften af et brændstofcelleanlæg og brændstofcelleanlæg
DK0625586T3 (da) Konstruktionselement og fremgangsmåde til fremstilling af dette
DE69415632D1 (de) Filamentwickelverfahren und -vorrichtung
DK0974842T3 (da) Reagensmiddel til undersøgelse af virus-agglutination og sæt til virusundersøgelse
DK55695A (da) Batteripakning og fremgangsmåde til fremstilling af en sådan
NO983082D0 (no) FremgangsmÕte og innretning for energiutvikling
DK0759879T3 (da) Fremgangsmåde og indretning til overføring af moduler
DK241790D0 (da) Fremgangsmaade til fremstilling af sucralfat og aai-10001
DK15498A (da) Indretning og fremgangsmåde til håndtering af returemballage
NO995564L (no) Fremgangsmåte og konstruksjon for inhibisjon av cellemigrering
FI953614A0 (fi) Soiton suoritusjärjestelmä ja -menetelmä